Alvotech (ALVO) Stock Forecast, Price Target & Predictions
ALVO Stock Forecast
Alvotech stock forecast is as follows: an average price target of $16.00 (represents a 23.84% upside from ALVO’s last price of $12.92) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
ALVO Price Target
ALVO Analyst Ratings
Alvotech Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
May 24, 2024 | Balaji Prasad | Barclays | $22.00 | $13.58 | 62.00% | 70.28% |
May 21, 2024 | Balaji Prasad | Barclays | $20.00 | $13.76 | 45.35% | 54.80% |
Jan 29, 2024 | Balaji Prasad | Barclays | $17.00 | $15.25 | 11.48% | 31.58% |
Jul 01, 2022 | Emmanuel Papadakis | Deutsche Bank | $10.00 | $8.21 | 21.80% | -22.60% |
Alvotech Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 3 |
Avg Price Target | - | - | $19.67 |
Last Closing Price | $12.92 | $12.92 | $12.92 |
Upside/Downside | -100.00% | -100.00% | 52.24% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
May 21, 2024 | Barclays | Overweight | Overweight | Hold |
Jan 29, 2024 | Barclays | - | Overweight | Upgrade |
Oct 20, 2023 | Citigroup | - | Neutral | Upgrade |
Jul 01, 2022 | Deutsche Bank | - | Hold | Initialise |
Alvotech Financial Forecast
Alvotech Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Jun 23 | |
---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - |
Avg Forecast | $89.86M | $82.41M | $75.59M | $69.32M | $115.50M | $85.00M | $53.48M | $93.00M | $42.00M |
High Forecast | $89.86M | $82.41M | $75.59M | $69.32M | $115.50M | $89.16M | $53.48M | $93.00M | $42.00M |
Low Forecast | $89.86M | $82.41M | $75.59M | $69.32M | $115.50M | $80.83M | $53.48M | $93.00M | $42.00M |
# Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
Surprise % | - | - | - | - | - | - | - | - | - |
Alvotech EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Jun 23 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
EBITDA | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-89.86M | $-82.41M | $-75.59M | $-69.32M | $-115.50M | $-85.00M | $-53.48M | $-93.00M | $-42.00M |
High Forecast | $-89.86M | $-82.41M | $-75.59M | $-69.32M | $-115.50M | $-80.83M | $-53.48M | $-93.00M | $-42.00M |
Low Forecast | $-89.86M | $-82.41M | $-75.59M | $-69.32M | $-115.50M | $-89.16M | $-53.48M | $-93.00M | $-42.00M |
Surprise % | - | - | - | - | - | - | - | - | - |
Alvotech Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Jun 23 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
Net Income | - | - | - | - | - | - | - | - | - |
Avg Forecast | $25.43M | $31.85M | $12.57M | $14.25M | $2.79M | $-16.76M | $838.22K | $11.74M | $-39.12M |
High Forecast | $25.43M | $31.85M | $12.57M | $14.25M | $2.79M | $-16.76M | $838.22K | $11.74M | $-39.12M |
Low Forecast | $25.43M | $31.85M | $12.57M | $14.25M | $2.79M | $-16.76M | $838.22K | $11.74M | $-39.12M |
Surprise % | - | - | - | - | - | - | - | - | - |
Alvotech SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Jun 23 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
SG&A | - | - | - | - | - | - | - | - | - |
Avg Forecast | $139.83M | $128.24M | $117.62M | $107.87M | $179.73M | $132.27M | $83.22M | $144.72M | $65.36M |
High Forecast | $139.83M | $128.24M | $117.62M | $107.87M | $179.73M | $138.73M | $83.22M | $144.72M | $65.36M |
Low Forecast | $139.83M | $128.24M | $117.62M | $107.87M | $179.73M | $125.79M | $83.22M | $144.72M | $65.36M |
Surprise % | - | - | - | - | - | - | - | - | - |
Alvotech EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Jun 23 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
EPS | - | - | - | - | - | - | - | - | - |
Avg Forecast | $0.09 | $0.11 | $0.04 | $0.05 | $0.01 | $-0.06 | - | $0.04 | $-0.14 |
High Forecast | $0.09 | $0.11 | $0.04 | $0.05 | $0.01 | $-0.06 | - | $0.04 | $-0.14 |
Low Forecast | $0.09 | $0.11 | $0.04 | $0.05 | $0.01 | $-0.06 | - | $0.04 | $-0.14 |
Surprise % | - | - | - | - | - | - | - | - | - |
Alvotech Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
ASRT | Assertio | $1.06 | $2.88 | 171.70% | Buy |
PCRX | Pacira BioSciences | $16.45 | $40.00 | 143.16% | Hold |
ANIP | ANI Pharmaceuticals | $56.01 | $79.00 | 41.05% | Buy |
AMPH | Amphastar Pharmaceuticals | $50.59 | $66.00 | 30.46% | Buy |
CTLT | Catalent | $58.69 | $76.40 | 30.18% | Hold |
CYTH | Cyclo Therapeutics | $0.73 | $0.95 | 30.14% | Buy |
ALKS | Alkermes | $26.59 | $34.38 | 29.30% | Hold |
COLL | Collegium Pharmaceutical | $32.72 | $41.50 | 26.83% | Buy |
ALVO | Alvotech | $12.92 | $16.00 | 23.84% | Hold |
ITCI | Intra-Cellular Therapies | $86.17 | $94.50 | 9.67% | Buy |
LFCR | Lifecore Biomedical | $5.99 | $6.50 | 8.51% | Buy |
ALVO Forecast FAQ
Is Alvotech a good buy?
No, according to 3 Wall Street analysts, Alvotech (ALVO) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 33.33% of ALVO's total ratings.
What is ALVO's price target?
Alvotech (ALVO) average price target is $16 with a range of $10 to $22, implying a 23.84% from its last price of $12.92. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Alvotech stock go up soon?
According to Wall Street analysts' prediction for ALVO stock, the company can go up by 23.84% (from the last price of $12.92 to the average price target of $16), up by 70.28% based on the highest stock price target, and down by -22.60% based on the lowest stock price target.
Can Alvotech stock reach $20?
ALVO's highest twelve months analyst stock price target of $22 supports the claim that Alvotech can reach $20 in the near future.
What are Alvotech's analysts' financial forecasts?
Alvotech's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $253.98M (high $258.14M, low $249.82M), average EBITDA is $-254M (high $-250M, low $-258M), average net income is $-13.132M (high $-13.132M, low $-13.132M), average SG&A $395.22M (high $401.68M, low $388.73M), and average EPS is $-0.047 (high $-0.047, low $-0.047). ALVO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $317.18M (high $317.18M, low $317.18M), average EBITDA is $-317M (high $-317M, low $-317M), average net income is $84.1M (high $84.1M, low $84.1M), average SG&A $493.56M (high $493.56M, low $493.56M), and average EPS is $0.301 (high $0.301, low $0.301).